Ticker Details
Rocket Pharmaceuticals, Inc. Rocket Pharmaceuticals Inc, formerly Inotek Pharmaceuticals Corp, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.
IPO Date:	February 18, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$392.84M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.58 | 3.05%
Avg Daily Range (30 D):	$0.16 | 3.55%
Avg Daily Range (90 D):	$0.12 | 3.16%

Institutional Daily Volume
Avg Daily Volume:	.84M
Avg Daily Volume (30 D):	4.07M
Avg Daily Volume (90 D):	2.66M

Trade Size
Avg Trade Size (Sh.):	100
Avg Trade Size (Sh.) (30 D):	175
Avg Trade Size (Sh.) (90 D):	173

Institutional Trades
Total Institutional Trades:	2,748
Avg Institutional Trade:	$2.02M
Avg Institutional Trade (30 D):	$1.79M
Avg Institutional Trade (90 D):	$1.93M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.29M
Avg Closing Trade (30 D):	$1.51M
Avg Closing Trade (90 D):	$1.34M
Avg Closing Volume:	137.49K

News

Oct 23, 2025 @ 10:03 PM ROCKET ALERT: Bragar Eagel & Squire, P.C. is Inves... Source: Bragar Eagel & Squire, P.C.

Aug 11, 2025 @ 4:00 PM DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offic... Source: Law Offices Of Howard G. Smith

Aug 10, 2025 @ 3:38 PM RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR CO... Source: Rosen Law Firm

Aug 8, 2025 @ 4:38 PM Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT)... Source: Business Wire

Aug 7, 2025 @ 11:45 PM MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & ... Source: Robbins Geller Rudman & Dowd Llp

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-2.01	$-.38	$-2.01
Diluted EPS	$-2.01	$-.38	$-2.01
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-223.12M	$-42.54M	$-223.12M
Operating Income / Loss	$-231.75M	$-43.96M	$-231.75M
Cost of Revenue
Net Cash Flow	$-86.1M	$1.59M	$-86.1M
PE Ratio

Splits
Jan 05, 2018	1:4